GENFIT |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.185 EUR | -1.70% |
|
-1.70% | -10.03% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.
The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Calendar
2024-05-13
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.24
EUR
Average target price
9.38
EUR
Spread / Average Target
+189.51%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.03% | 171M | |
| -0.10% | 42.07B | |
| +48.43% | 42.16B | |
| +4.43% | 39.77B | |
| -11.36% | 26.68B | |
| +5.67% | 24.68B | |
| -22.84% | 18.68B | |
| -0.20% | 12.11B | |
| +26.30% | 11.99B | |
| +6.91% | 11.06B |
- Stock Market
- Equities
- GNFT Stock
- News GENFIT
- Genfit : Loss Widens Last Year as Revenue Slumps
